[go: up one dir, main page]

CA2991984A1 - Peptides inhibiteurs du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires - Google Patents

Peptides inhibiteurs du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires Download PDF

Info

Publication number
CA2991984A1
CA2991984A1 CA2991984A CA2991984A CA2991984A1 CA 2991984 A1 CA2991984 A1 CA 2991984A1 CA 2991984 A CA2991984 A CA 2991984A CA 2991984 A CA2991984 A CA 2991984A CA 2991984 A1 CA2991984 A1 CA 2991984A1
Authority
CA
Canada
Prior art keywords
phe
pen
lys
aminoethoxy
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2991984A
Other languages
English (en)
Inventor
Ashok Bhandari
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/fr
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of CA2991984A1 publication Critical patent/CA2991984A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouveaux peptides inhibiteurs du récepteur de l'interleukine-23 et des compositions associées et des procédés d'utilisation de ces peptides inhibiteurs pour traiter ou prévenir divers troubles et maladies, notamment les maladies inflammatoires de l'intestin.
CA2991984A 2015-07-15 2016-07-15 Peptides inhibiteurs du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires Pending CA2991984A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
USPCT/US15/40658 2015-07-15
US14/800,627 2015-07-15
PCT/US2015/040658 WO2016011208A1 (fr) 2014-07-17 2015-07-15 Peptides inhibiteurs par voie orale du récepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US62/264,820 2015-12-08
US201662281123P 2016-01-20 2016-01-20
US62/281,123 2016-01-20
PCT/US2016/042680 WO2017011820A2 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires

Publications (1)

Publication Number Publication Date
CA2991984A1 true CA2991984A1 (fr) 2017-01-19

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991984A Pending CA2991984A1 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires

Country Status (23)

Country Link
EP (1) EP3341011A4 (fr)
JP (1) JP6858174B2 (fr)
KR (1) KR102513978B1 (fr)
CN (1) CN108348580B (fr)
AU (1) AU2016293619B2 (fr)
BR (1) BR112018000691A2 (fr)
CA (1) CA2991984A1 (fr)
CL (3) CL2018000128A1 (fr)
CO (1) CO2018000349A2 (fr)
CR (1) CR20180029A (fr)
DO (1) DOP2018000010A (fr)
EA (1) EA035733B9 (fr)
EC (1) ECSP18002929A (fr)
HK (1) HK1257747A1 (fr)
IL (1) IL256827A (fr)
MX (1) MX384213B (fr)
NI (1) NI201800008A (fr)
PE (1) PE20180571A1 (fr)
PH (1) PH12018500086A1 (fr)
SG (1) SG10201912066SA (fr)
SV (1) SV2018005614A (fr)
UA (1) UA123772C2 (fr)
WO (1) WO2017011820A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
WO2017117411A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimétiques d'hepcidine à demi-vie in vivo améliorée
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
WO2018136646A1 (fr) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP4092038A1 (fr) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Peptides d'agoniste opioïde et leurs utilisations
EP4501952A3 (fr) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020014646A1 (fr) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
BR112021026815A2 (pt) * 2019-07-01 2022-06-07 Valitor Inc Ligantes hidrofílicos para conjugados de peptídeo multivalentes
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3997105A4 (fr) * 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (fr) 2019-11-07 2021-05-12 CytoKi Pharma ApS Dérivés thérapeutiques de l'interleukine-22
WO2021113462A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Dérivés d'un inhibiteur de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
MX2022016012A (es) * 2020-06-29 2023-03-10 Univ Washington Polipéptidos de unión al receptor de la il-23 humana.
CA3194956A1 (fr) 2020-09-11 2022-03-17 Glympse Bio, Inc. Detection d'activite de protease ex vivo pour la detection/le diagnostic, la stadification, le suivi et le traitement de maladies
IL302996B2 (en) * 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
JP2023145581A (ja) * 2020-11-20 2023-10-11 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
WO2022261159A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
EP4370531A4 (fr) * 2021-07-14 2025-09-03 Janssen Biotech Inc Inhibiteurs peptidiques du récepteur de l'interleukine-23
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
MX2024000761A (es) * 2021-07-14 2024-04-18 Janssen Biotech Inc Inhibidores peptidicos biciclicos del receptor de interleucina-23.
CA3240982A1 (fr) 2021-12-01 2023-06-08 Zealand Pharma A/S Inhibiteurs peptidiques du recepteur de l'interleukine-23
US20250223627A1 (en) * 2022-03-09 2025-07-10 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
JP2025521647A (ja) 2022-06-30 2025-07-10 サノフイ 選択的ｉｌ－２３受容体アンタゴニストとしての新規ペプチド
AU2023386710A1 (en) * 2022-11-21 2025-07-10 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
EP4652180A2 (fr) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Inhibiteurs peptidiques du récepteur de l'interleukine-23
CN121127485A (zh) * 2023-01-16 2025-12-12 詹森药业有限公司 白介素-23受体的多环肽抑制剂
WO2024163643A1 (fr) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Procédés de préparation d'inhibiteurs peptidiques cristallins du récepteur de l'interleukine-23
WO2024227437A1 (fr) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 Préparation d'un inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation
EP4471048A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
EP4471049A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2025051920A1 (fr) 2023-09-08 2025-03-13 Sanofi Nouveaux peptides en tant qu'inhibiteurs sélectifs du récepteur de l'il-23
WO2025051912A1 (fr) 2023-09-08 2025-03-13 Sanofi Nouveaux peptides en tant qu'inhibiteurs sélectifs du récepteur de l'il-23

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
CN101990547A (zh) * 2007-07-06 2011-03-23 瓦勒瑞萨欣Hsj有限合伙公司 Il-23受体拮抗剂以及其应用
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
EP3065757A4 (fr) * 2013-10-09 2017-08-23 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour la régulation négative de cytokines pro-inflammatoires
ES2977537T3 (es) * 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales

Also Published As

Publication number Publication date
IL256827A (en) 2018-03-29
KR102513978B1 (ko) 2023-03-27
EA035733B1 (ru) 2020-07-31
HK1259149A1 (zh) 2019-11-29
JP2018522008A (ja) 2018-08-09
BR112018000691A2 (pt) 2018-09-18
CL2021000343A1 (es) 2021-08-06
PE20180571A1 (es) 2018-04-04
CL2018000128A1 (es) 2018-06-15
CO2018000349A2 (es) 2018-07-10
EA035733B9 (ru) 2021-01-14
EP3341011A2 (fr) 2018-07-04
SV2018005614A (es) 2018-05-22
CN108348580A (zh) 2018-07-31
CR20180029A (es) 2018-06-05
MX2018000542A (es) 2018-06-27
AU2016293619A1 (en) 2018-02-01
UA123772C2 (uk) 2021-06-02
MX384213B (es) 2025-03-14
EP3341011A4 (fr) 2019-02-20
AU2016293619B2 (en) 2021-02-25
DOP2018000010A (es) 2018-03-30
CL2018003322A1 (es) 2019-01-18
SG10201912066SA (en) 2020-02-27
ECSP18002929A (es) 2018-03-31
EA201890325A1 (ru) 2018-06-29
WO2017011820A3 (fr) 2017-02-23
JP6858174B2 (ja) 2021-04-14
NI201800008A (es) 2018-06-29
HK1257747A1 (zh) 2019-10-25
PH12018500086A1 (en) 2018-07-30
CN108348580B (zh) 2022-05-10
WO2017011820A2 (fr) 2017-01-19
KR20180030663A (ko) 2018-03-23

Similar Documents

Publication Publication Date Title
US20240199700A1 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
AU2016293619B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10787490B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2018210174B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK1259149B (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714